Subtype
Digestive System Neuroendocrine Tumor
CI-CAN-00000823Explore in graph →
Non-malignant62 active trials1 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000823Explore in graph →
Clinical trials
256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05568017 | Neoadjuvant PRRT With Y-90-DOTATOC in pNET(NeoNet) | terminated | Phase 2 | 11 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06024343 | Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction | completed | N/A | 230 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06557408 |
| Pancreatic Fistula After Minimally Invasive Enucleation |
| completed |
| — |
| 173 |
| Fudan UniversityOTHER |
| 1 |
| Nov 7, 2024 |
| clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06041009 | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | recruiting | — | 2,100 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04852679 | Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs(PALACE) | completed | Phase 3 | 43 | IpsenINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02021604 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | recruiting | Phase 1 | 250 | Cook Children's Health Care SystemOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05701241 | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients(SAUNA) | recruiting | Phase 4 | 270 | University Hospital, AntwerpOTHER | 2 | Jun 14, 2024 | clinicaltrials |
| NCT06246630 | In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor | unknown | N/A | 20 | Ruijin HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06402695 | Observational Study on GEP-and Pulm-NET Treated at FPG(ETNA-FPG) | unknown | — | 650 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05359146 | Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)(Beta plus) | unknown | Early Phase 1 | 16 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05476978 | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions | completed | — | 130 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03084770 | Asymptomatic Small Pancreatic Endocrine Neoplasms.(ASPEN) | unknown | — | 1,000 | IRCCS San RaffaeleOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06155318 | 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours | recruiting | — | 300 | IRCCS San RaffaeleOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04452396 | CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia | terminated | N/A | 7 | Barts & The London NHS TrustOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06167421 | Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy | not yet recruiting | N/A | 240 | Fudan UniversityOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT05709171 | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | unknown | Phase 2 | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02264665 | OPALINE : A Study Of Morbidity And Mortality At 2 Years(OPALINE) | completed | — | 144 | PfizerINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05523778 | A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct | unknown | N/A | 78 | Peking Union Medical College HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06080204 | Real-world Study on Adjuvant Octreotide Therapy in pNETs | completed | N/A | 411 | Changhai HospitalOTHER | 0 | Oct 18, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05448157 | 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET(RGS-GEP-NET) | unknown | — | 20 | European Institute of OncologyOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04979611 | The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | unknown | Phase 1 | 60 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05907824 | Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm | unknown | — | 800 | Fudan UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05171517 | Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy | completed | — | 200 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05243082 | Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms(ERFA-PNET) | recruiting | N/A | 20 | Oslo University HospitalOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03918759 | Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs | completed | — | 100 | IRCCS San RaffaeleOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04915144 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | withdrawn | Phase 2 | 0 | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT01842165 | 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs(LUMEN) | completed | Phase 3 | 37 | Jules Bordet InstituteOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03722511 | Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs | completed | Phase 2 | 10 | Lowell Anthony, MDOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02608203 | [68 Ga]-DOTANOC PET/CT in GEP-NETs(GEP-NOC) | completed | Phase 2 / Phase 3 | 18 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05034783 | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05566093 | EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors | unknown | N/A | 20 | Guangxi Medical UniversityOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg(CLARINET FORTE) | completed | Phase 2 | 99 | IpsenINDUSTRY | 10 | Oct 3, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2024source: clinicaltrials